|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
Statistics. CA Cancer J Clin. 59:225–249. 2009.
|
|
2
|
Schiller JH, Harrington D, Belani CP, et
al Eastern Cooperative Oncology Group: Comparison of four
chemotherapy regimens for advanced non-small-cell lung cancer. N
Engl J Med. 346:92–98. 2002. View Article : Google Scholar
|
|
3
|
Ohe Y, Ohashi Y, Kubota K, et al:
Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beer DG, Kardia SL, Huang CC, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002.PubMed/NCBI
|
|
7
|
Potti A, Mukherjee S, Petersen R, et al: A
genomic strategy to refine prognosis in early-stage non-small-cell
lung cancer. N Engl J Med. 355:570–580. 2006. View Article : Google Scholar
|
|
8
|
Seike M, Yanaihara N, Bowman ED, et al:
Use of a cytokine gene expression signature in lung adenocarcinoma
and the surrounding tissue as a prognostic classifier. J Natl
Cancer Inst. 99:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zavadil J and Bottinger EP: TGF-β and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005.
|
|
11
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-β family signalling. Nature.
425:577–584. 2003.
|
|
12
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh A, Greninger P, Rhodes D, et al: A
gene expression signature associated with ‘K-Ras addiction’ reveals
regulators of EMT and tumor cell survival. Cancer Cell. 15:489–500.
2009.
|
|
16
|
Mizutani H, Okano T, Minegishi Y, et al:
HSP27 modulates epithelial to mesenchymal transition of lung cancer
cells in a Smad-independent manner. Oncol Lett. 1:1011–1016.
2010.PubMed/NCBI
|
|
17
|
Yauch RL, Januario T, Eberhard DA, et al:
Epithelial versus mesenchymal phenotype determines in vitro
sensitivity and predicts clinical activity of erlotinib in lung
cancer patients. Clin Cancer Res. 11:8686–8698. 2005. View Article : Google Scholar
|
|
18
|
Thomson S, Buck E, Petti F, et al:
Epithelial to mesenchymal transition is a determinant of
sensitivity of non-small-cell lung carcinoma cell lines and
xenografts to epidermal growth factor receptor inhibition. Cancer
Res. 65:9455–9462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rho JK, Choi YJ, Lee JK, et al: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Lung Cancer. 63:219–226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson SM, Grosshans H, Shingara J, et
al: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Volinia S, Calin GA, Liu CG, et al: A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayashita Y, Osada H, Tatematsu Y, et al:
A polycistronic microRNA cluster, miR-17-92, is overexpressed in
human lung cancers and enhances cell proliferation. Cancer Res.
65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seike M, Goto A, Okano T, et al: MiR-21 is
an EGFR-regulated anti-apoptotic factor in lung cancer in
never-smokers. Proc Natl Acad Sci USA. 106:12085–12090. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang S, He X, Ding J, et al: Upregulation
of miR-23a approximately 27a approximately 24 decreases
transforming growth factor-beta-induced tumor-suppressive
activities in human hepatocellular carcinoma cells. Int J Cancer.
123:972–978. 2008. View Article : Google Scholar
|
|
27
|
Bustin SA: Absolute quantification of mRNA
using real-time reverse transcription polymerase chain reaction
assays. J Mol Endocrinol. 25:169–193. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saito RA, Watabe T, Horiguchi K, et al:
Thyroid transcription factor-1 inhibits transforming growth
factor-beta-mediated epithelial-to-mesenchymal transition in lung
adenocarcinoma cells. Cancer Res. 69:2783–2791. 2009. View Article : Google Scholar
|
|
29
|
Soltermann A, Tischler V, Arbogast S, et
al: Prognostic significance of epithelial-mesenchymal and
mesenchymal-epithelial transition protein expression in non-small
cell lung cancer. Clin Cancer Res. 14:7430–7437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gregory PA, Bert AG, Paterson EL, et al:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Korpal M, Lee ES, Hu G, et al: The miR-200
family inhibits epithelial-mesenchymal transition and cancer cell
migration by direct targeting of E-cadherin transcriptional
repressors ZEB1 and ZEB2. J Biol Chem. 283:14910–14914. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tryndyak VP, Beland FA and Pogribny IP:
E-cadherin transcriptional down-regulation by epigenetic and
microRNA-200 family alterations is related to mesenchymal and
drug-resistant phenotypes in human breast cancer cells. Int J
Cancer. 126:2575–2583. 2010.PubMed/NCBI
|
|
33
|
Kong W, Yang H, He L, et al: MicroRNA-155
is regulated by the transforming growth factor beta/Smad pathway
and contributes to epithelial cell plasticity by targeting RhoA.
Mol Cell Biol. 28:6773–6784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma L, Young J, Prabhala H, et al: miR-9, a
MYC/MYCN-activated microRNA, regulates E-cadherin and cancer
metastasis. Nat Cell Biol. 12:247–256. 2010.PubMed/NCBI
|
|
35
|
Zhu LH, Liu T, Tang H, et al: MicroRNA-23a
promotes the growth of gastric adenocarcinoma cell line MGC803 and
downregulates interleukin-6 receptor. FEBS J. 277:3726–3734. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gao P, Tchernyshyov I, Chang TC, et al:
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase
expression and glutamine metabolism. Nature. 458:762–765. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Inoue A, Kobayashi K, Usui K, et al:
First-line gefitinib for patients with advanced non-small-cell lung
cancer harboring epidermal growth factor receptor mutations without
indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bremnes RM, Veve R, Gabrielson E, et al:
High-throughput tissue microarray analysis used to evaluate biology
and prognostic significance of the E-cadherin pathway in
non-small-cell lung cancer. J Clin Oncol. 20:2417–2428. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Witta SE, Gemmill RM, Hirsch FR, et al:
Restoring E-cadherin expression increases sensitivity to epidermal
growth factor receptor inhibitors in lung cancer cell lines. Cancer
Res. 66:944–945. 2006. View Article : Google Scholar : PubMed/NCBI
|
